Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05UJS
|
|||
| Former ID |
DNCL003015
|
|||
| Drug Name |
ADVAX
|
|||
| Indication | Human immunodeficiency virus infection [ICD-11: 1C62; ICD-9: 279.3] | Phase 1 | [1] | |
| Company |
Aaron Diamond AIDS Research Center; International AIDS Vaccine Initiative Ichor Medical Systems
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | TNF-alpha signaling pathway (TNFA pathway) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00902824) Safety and Immunogenicity of TBC-M4, a MVA HIV Vaccine Alone or in a Prime-Boost Regimen With ADVAX DNA HIV Vaccine. U.S. National Institutes of Health. | |||
| REF 2 | Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine. PLoS One. 2010 Jan 25;5(1):e8617. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.